What is Mirvie?
Mirvie is at the forefront of transforming prenatal care by developing a proprietary RNA platform that enables early detection of pregnancy complications. Utilizing a simple blood test, the platform analyzes a pregnancy's unique biological markers to identify potential issues months in advance, thereby allowing for timely intervention. This technology addresses a significant unmet need, as pregnancy complications can lead to lifelong health consequences for both parents and babies. The company's scientific team comprises world-class experts with a proven track record in bringing category-first, non-invasive tests to market in women's health and cancer detection. Founded in 2018, Mirvie has already garnered substantial early-stage financing, signaling strong investor belief in its disruptive potential within the maternal health and biotechnology industries.
How much funding has Mirvie raised?
Mirvie has raised a total of $89.5M across 3 funding rounds:
Angel/Seed
$5.8M
Series B
$60M
Private Equity
$23.7M
Angel/Seed (2018): $5.8M with participation from Khosla Ventures
Series B (2022): $60M led by Foresite Capital, GV, Decheng Capital, Mayfield, Khosla Ventures, BlackRock, Comerica, and General Catalyst
Private Equity (2025): $23.7M, investors not publicly disclosed
Key Investors in Mirvie
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach.
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors. The company focuses on enterprise solutions, life sciences, consumer products, and frontier technology innovations.
Decheng Capital
Decheng Capital is a global investment firm established in 2012, specializing in providing capital and strategic support to early-stage life science companies and growth stage healthcare companies. With over $2.1 billion in capital, the firm aims to build legendary companies by leveraging revolutionary technologies and strong market presence.
What's next for Mirvie?
With the recent major strategic investment and a history of substantial early-stage financing, Mirvie is well-positioned for accelerated scaling and market penetration. The company's focus on early detection of pregnancy complications through its advanced RNA platform suggests a strategic roadmap centered on clinical validation, regulatory approvals, and commercialization. Future growth will likely involve expanding its scientific research, forging partnerships with healthcare providers and institutions, and enhancing its technological capabilities. The substantial backing indicates a trajectory towards becoming a leader in predictive diagnostics for maternal health, potentially reshaping standard obstetric care and improving outcomes for countless families worldwide.
See full Mirvie company page
